When is allogeneic stem cell transplant recommended for myelodysplastic syndromes?

The transplant uses blood-forming stem cells from another person. Before the cells are given, conditioning treatment reduces abnormal marrow cells and suppresses immune activity so the donor cells can settle in the marrow. The new immune system may also recognise remaining abnormal cells.

A team weighs marrow findings, chromosome or gene changes, blood counts, transfusion needs, disease progression, age, other illnesses, physical fitness, donor matching, and personal priorities. Lower-risk disease may be managed with monitoring, supportive care, or medicines when transplant risks outweigh likely benefit.

Ask for a transplant consultation early if your haematologist says the disease is higher risk or changing. The assessment can include heart, lung, kidney, liver, infection, dental, and fitness checks. Your team may discuss disease control before transplant, donor search, fertility preservation, medicines, vaccinations, and support at home.

Compare transplant with non-transplant options in terms of treatment burden, possible complications, recovery, effects on daily life, and what happens if the disease changes. Bring a medication list and a trusted support person to appointments.

During treatment or after transplant, contact the transplant team promptly for a fever, chills, new breathlessness, chest pain, confusion, uncontrolled bleeding, severe diarrhoea, inability to drink, or a rapidly worsening rash. Low blood counts can make infection or bleeding urgent even when symptoms seem mild.

Useful questions include: What features place my MDS in a higher-risk group? Am I fit enough for transplant? What donor options are being explored? Should treatment start before transplant? Which side effects require an immediate call? How long might close monitoring and help at home be needed?